Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Marketing Unaffected By Proposed Risk Management Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

Marketing of Biogen Idec/Elan's Tysabri would not be restricted by the companies' proposed risk management plan, CDER Office of Medical Policy Director Robert Temple said during a press briefing following an advisory committee meeting on the product's reintroduction

You may also be interested in...



Tysabri Return To Market For First-Line Use In Relapsed MS Supported By Slim Majority

FDA advisory committee unanimously agrees that Biogen Idec's natalizumab should be reintroduced for at least some multiple sclerosis patients.

Tysabri Return To Market For First-Line Use In Relapsed MS Supported By Slim Majority

FDA advisory committee unanimously agrees that Biogen Idec's natalizumab should be reintroduced for at least some multiple sclerosis patients.

Tysabri Revised RiskMAP Would Have Mandatory Patient/Physician Registry Enrollment

Biogen Idec’s revised risk management plan for its multiple sclerosis therapy Tysabri adopts most changes sought by FDA in a critique of the company’s original risk plan.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel